Advance WP1244 development for CNS tumors
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- 31 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“WP1244 CNS tumors 2021”
What we found
Evidence strength A What the grades mean
The company funded research under a Sponsored Research Agreement throughout 2021, which resulted in the development of a new WP1244 derivative, WP1874, becoming the primary focus of their development efforts.
-
A CNS Pharmaceuticals, Inc. 10-K filed 2022-03-03
“The work conducted under this Sponsored Research Agreement has produced a new mesylate salt of WP1244 termed WP1874. We believe the enhanced solubility of this salt may increase its ability to be formulated for use in an IV infusion... As such, WP1874 will be the primary focus in our development eff” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Advance
- Deliverable
- WP1244 development for CNS tumors
- In the company’s control
- High
- Specificity
- Low
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you CNS Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CNSP-021333 · Corrections policy